You just read:

Aimovig™ (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention

News provided by

Amgen

Nov 29, 2017, 17:00 ET